We are excited to announce that Dr. Hassan Serhan, a former Distinguished Fellow at Johnson & Johnson, has joined the CarthroniX Board of Directors and was appointed as the new CEO. Dr. Serhan is a seasoned professional in executive level management of large programs and complex corporate environments, and has more than 15 years of experience in identifying and growing disruptive technologies while at Johnson and Johnson. 

Dr. Serhan’s vast leadership experience, as well as his passion for translating cutting-edge areas of science into novel therapeutics, makes him the ideal leader for CarthroniX as we press forward in our mission to harness the regenerative power of inflammation and develop a new class of small molecule-based therapeutics to modulate gp130 for degenerative and aging-related diseases, including arthritis, idiopathic pulmonary fibrosis and oncology.